Ascend Laboratories received FDA approval for its Generic Dapagliflozin and Metformin Hydrochloride tablets, a critical oral combination therapy for type 2 diabetes. This launch is expected to intensify competitive pricing and pressure leading brands in this high-turnover therapeutic class.